Trial Profile
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Brentuximab vedotin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 14 Sep 2023 Planned End Date changed from 7 Aug 2024 to 8 Jul 2025.
- 15 Aug 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 13 Dec 2022 Results reporting efficacy and safety data with a median follow-up of 22 months presented at the 64th American Society of Hematology Annual Meeting and Exposition